Eisai builds Chinese GI portfolio with Almirall deal
This article was originally published in Scrip
Eisai has acquired rights to Almirall's gastroprokinetic agent cinitapride in China, in a deal which extends the Japanese firm's gastrointestinal (GI) portfolio in this fast-growing market.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.